Serevent News
FDA Requests Additional Information From Makers of Asthma Drugs ... - StreetInsider.com (subscription)
... PLC's (NYSE: GSK) Serevent and Advair, Novartis AG's (NYSE: NVS) and Schering-Plough's (NYSE: SGP) Foradil and AstraZeneca's (NYSE: AZN) Symbicort. ...
FDA: Seeking Additional Information On Asthma Drugs - CNNMoney.com
The guidelines recommend that drugs such as Serevent, Advair and Foradil should be used only as add-on therapy in patients 12 and older whose asthma isn't ...
FDA Updates Safety Information for Long Acting Beta Agonists - PharmaLive.com (press release)
On March 2, 2006, FDA approved new safety labeling and Medication Guides for patients for Serevent Diskus (salmeterol xinafoate) and Advair Diskus ...
FDA Seeks Info on Serevent, Advair, Foradil As Part of Safety Review - Newsinferno.com
Asthma drugs, including Serevent, Advair, Foradil, are the subject of a Food & Drug Administration (FDA) safety review. The FDA has requested information ...
GlaxoSmithKline (GSK) NewsBite - FDA Requests Data on ... - Market Intelligence Center
The request includes include Glaxo's Advair and Serevent drugs. Technical indicators for the stock are bearish and steady while S&P gives GSK a neutral 3 ...
US FDA requests more safety data on asthma drugs - Guardian
The drugs, known as long-acting beta agonists, include Glaxo's Advair and Serevent, Novartis AG's Foradil and AstraZeneca Plc's Symbicort. ...
Merck says 'goodbye, Fosamax,' launches authorized generic - Medical Marketing and Media
This month alone, upcoming patent losses will include GlaxoSmithKline asthma meds Advair ($6 billion in total sales) and Serevent ($500 million in total ...
FDA Panel Cites Glaxo Drugs' Asthma Risk - CNNMoney.com
"There is no new safety information that changes the benefit-risk evaluation of Serevent or Advair which warrants another review at this time," Glaxo said ...
FDA panel backs more warnings on Glaxo asthma drugs - MarketWatch
Serevent and Advair were the subject of a review Wednesday by the agency's pediatric advisory committee, which looked at the safety of products containing ...
Stronger Warnings Advised on Asthma Drug - New York Times
28 (Reuters) — Federal regulatory advisers on Wednesday recommended strengthening safety warnings on GlaxoSmithKline’s asthma drug Serevent amid reports of ...
Serevent RSS Feed